| 产品描述: | Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties. |
| 靶点: |
RORγ:10 nM (IC50) |
| 体内研究: |
Izumerogant 对 SARS-CoV-2、HCMV 和 HAdV5 表现出纳摩尔抑制活性,EC50 分别为 3.6 nM、17 nM 和 12 nM。 |
| 参考文献: |
1. F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.017 ml |
10.083 ml |
20.167 ml |
| 5 mM |
0.403 ml |
2.017 ml |
4.033 ml |
| 10 mM |
0.202 ml |
1.008 ml |
2.017 ml |
| 50 mM |
0.04 ml |
0.202 ml |
0.403 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |